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Background: Although cardiac resynchronization therapy (CRT) is effective for some patients 
with heart failure and a reduced left ventricular ejection fraction (HFrEF), evidence gaps remain 
for key clinical and policy areas. 
Objective: Review the data on the effects of CRT for patients with HFrEF receiving 
pharmacological therapy alone or pharmacological therapy and an ICD and then, informed by a 
diverse group of stakeholders, to identify evidence-gaps, prioritize them and develop a research 
plan. 
Method: Relevant studies were identified using PubMed and EMBASE and ongoing trials using 
clinicaltrials.gov. Forced-ranking prioritization method was applied by stakeholders to reach a 
consensus on the most important questions.  
Participants: Twenty-six stakeholders contributed to the expanded list of evidence gaps, 
including key investigators from existing RCTs and others representing different perspectives, 
including patients, the public, device manufacturers, and policymakers.  
Results: Of the 18 top-tier evidence gaps, 8 were related to specific populations or subgroups of 
interest. Seven were related to the comparative effectiveness and safety of CRT interventions or 
comparators, and three were related to the association of CRT treatment with specific outcomes.  
The association of comorbidities with CRT effectiveness ranked highest, followed by questions 
about the effectiveness of CRT among patients with atrial fibrillation and the relationship 
between gender, QRS morphology and duration, and outcomes for patients with either CRT-D or 
ICD.                 
Conclusion: Evidence gaps presented in this paper highlight numerous, important clinical and 
policy questions for which there is inconclusive evidence on the role of CRT and provide a 
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Cardiac resynchronization therapy (CRT), with or without an implantable cardioverter 
defibrillator device (ICD), is an important advance in the care of a selected group of patients 
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with heart failure (HF). Several landmark randomized clinical trials (RCTs) have demonstrated 
that CRT is an effective therapy for patients with symptomatic HF who have a reduced left 
ventricular ejection fraction (<35%; HFrEF), a prolonged QRS duration (≥130ms) and in sinus 
rhythm (1-4) in addition to pharmacological therapy alone or pharmacological therapy and an 
implantable cardioverter defibrillator (ICD) (5). CRT improves cardiac function, symptoms, 
quality of life and exercise capacity and reduces HF hospitalizations, ventricular arrhythmias, 
and mortality and is cost-effective (6-10). Although up to 14% of patients with HF meet the 
eligibility criteria for CRT, it appears generally underused, with great heterogeneity in its 
implementation in North America and Europe and elsewhere (11-13).  
Despite the clear benefits of CRT and strong endorsement in clinical guidelines for selected 
patients, many clinical and policy questions remain (14). Indeed, in 2009 the Institute of 
Medicine recommended that evaluating the effectiveness of CRT should be a top priority for 
future research (15). For patients, clinicians, payers, policymakers, and device manufacturers it 
remains important to identify and answer key questions about patient selection for CRT as well 
as device therapy optimization.  
The National Heart, Lung, and Blood Institute (NHLBI; R01 HL131754-03) funded the Duke 
University Evidence Synthesis Group (ESG) to synthesize the evidence related to CRT with the 
ultimate goal of developing decision support tools for patients, clinicians, and policymakers. An 
initial step in this process was to work with diverse stakeholders to identify and prioritize timely 
clinical and policy evidence gaps. Subsequent efforts will use decision modeling and Bayesian 
statistics to explore the high-priority gaps that we have identified using pooled patient-level data 
from existing RCTs and registries. This article summarizes the results of the topic prioritization 






Our approach to prioritizing the evidence gaps involved several steps that were initially 
developed by the Agency for Healthcare Research and Quality (AHRQ)’s Evidence-based 
Practice Center (EPC) Program (16) and followed our previous prioritization process (17) 
(Figure 1). These steps broadly involved seeking input from clinical experts and evaluating 
recent systematic reviews to identify a preliminary list of evidence gaps; transforming these gaps 
into research questions; selecting and engaging stakeholders to identify additional gaps and 
prioritize them; and reviewing recently published and ongoing studies that were relevant to the 
stakeholders’ list of priorities. Our team has used this process for similar work with AHRQ(18-
20) and with the Patient-Centered Outcomes Research Institute (PCORI)(17,21-23) which has 
informed their future research needs portfolio and targeted funding announcements. 
Identification of Evidence Gaps 
We applied an iterative process to identify evidence gaps for CRT use in patients with HF. 
First, the ESG team sought input from clinical experts at Duke University (SMA, DF, MF) and 
identified and evaluated recently published clinical practice guidelines, consensus statements, 
and systematic reviews in order to create an initial list of evidence gaps. This list was neither 
complete nor prioritized. Next, the evidence gaps were organized into broad topics within CRT 
and transformed into research questions.  
Selection and Engagement of Stakeholders 
Our aim was to establish a diverse panel of participants including clinicians, researchers, 
representatives from patient advocacy groups, federal and non-governmental funding agencies, 
cardiovascular professional societies, health care decision-makers and policymakers, and 
industry. The stakeholder group was developed using previously described taxonomy, and the 
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group included representatives of the following stakeholders groups identified in the 7P 
framework: patients and public, providers, purchasers, payers, policymakers, principal 
investigators, and product makers (16,24). Within each of these groups, we solicited participation 
of at least one person with content expertise and a unique viewpoint on the clinical area of CRT 
and its current uncertainties. We received stakeholder input at various points in the process 
through individual conference calls, group web-based conferences, and emails outlining the 
process and proposed list of evidence gaps. 
The stakeholder group (Supplemental Table 1) was asked to review and propose additional 
questions for prioritization and, through a series of four conference calls, the evidence gaps were 
discussed and expanded. Suggestions were reviewed by the ESG team, and a revised document 
with unique gaps in evidence across a broad range of topics was developed. The final document 
was shared with the stakeholders for review to ensure appropriate implementation of their 
suggestions. The final list included 40 identified research priorities (Supplemental Table 2). 
Prioritization of Future Research 
Stakeholders were invited to rank the expanded list of research priorities. They used a Likert 
scale to indicate how critical the gap was to decision making, followed by a forced-ranking 
prioritization method previously described by the AHRQ EPC’s Future Research Needs projects 
(16) and also used in the ICD prioritization project (17) by the ESG team. In this exercise, 
participants were allocated 15 votes that could be applied to any of the 40 identified research 
gaps, with a maximum of 3 votes per item. No set criteria were prescribed for the prioritization 
process; instead stakeholders were asked to determine the most important unanswered research 
questions on CRT. Stakeholders were also asked to self-report their perceived perspective as that 
of a patient, clinician, public, purchaser, payer, policymaker, device manufacturer, or principal 
investigator, with the understanding that individual stakeholders could embody more than one 
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perspective. Following these exercises, the evidence gaps were separated into three prioritization 
tiers (top, middle, lower). Only priorities in the top tier that were ranked as highest priority by at 
least one-third of stakeholders moved on to the horizon scan stage.  
Horizon Scan of Studies Potentially Relevant to Top-Tier Evidence Gaps 
The final step in the prioritization process included a scan of the current evidence pertinent to 
the identified top-tier research questions. To identify published research and ongoing studies, the 
ESG team searched the published literature using PubMed and EMBASE to identify relevant 
RCTs and prospective observational studies published since 2008 and applicable to the identified 
research gaps. Supplemental Table 3 provides the exact search strategies. Two independent 
ESG members reviewed the identified titles and abstracts for inclusion/exclusion. We included 
articles if they met the following criteria: (1) presented original data or secondary analysis of 
data from an RCT or prospective observational study and (2) included data related to CRT use 
with a stated objective that could be categorized according to our identified list of research 
priorities. Articles included by either reviewer underwent abstraction of their applicability to 
identified evidence gaps. One team member abstracted the data, and a second (SMA or MF) 
over-read the accompanying abstraction to check for accuracy and completeness. All results 
were tracked using the DistillerSR data synthesis software program (Evidence Partners Inc., 
Manotick, ON, Canada). 
We also searched clinicaltrials.gov (October 5, 2018) using the term “cardiac 
resynchronization therapy” and searched for ongoing and recently completed but unpublished 
studies. ESG team members reviewed all study summaries identified by the search and marked 
them as potentially pertinent to one or more of the identified research priorities. We then 





A total of 26 stakeholders were included in different steps of our prioritization process, of 
whom 22 (84.6%) provided input on the evidence gaps list. The stakeholders represented an 
array of different expertise and perspectives and self-identified as clinician (N=14), clinical 
researcher (N=18), patient/public (N=3), policymaker (N=1), device manufacturer (N=2), or 
other (health technology assessor, N=1). We included principal or key investigators from each of 
the existing RCTs of CRT who also served on our PI Leadership Group (PILG), and therefore 
the perspective of clinical researchers was strongly represented in our stakeholder group (69% of 
stakeholders).  
We consolidated the questions into four broad categories of CRT evidence gaps: (1) specific 
population or subgroup of interest; (2) comparative safety and effectiveness of available 
interventions or comparators; (3) association of treatment with specific outcomes of interest; and 
(4) optimal timing or setting for treatment. 
Ranked Future Research 
After the expanded list of evidence gaps was identified, a total of 21 stakeholders contributed 
to the online prioritization process. The initial prioritization rankings from the stakeholders 
ranging from “of critical importance” (rank=9) to “of limited importance” (rank=0) are presented 
in Supplemental Table 4. Next, the forced ranking prioritization process produced the final 
score of prioritizations ranking for each evidence gap (Table 1). The ranked gaps are 
accompanied by the number of voting stakeholders, the total score, and the perspective 
represented by these votes. The evidence gaps considered as top-tier priority are shaded in gray 
and represent those in the top third through forced ranking (top 14 of the original 40 evidence 
gaps) or that were rated as critical to decision making by greater than 40% of the stakeholders 
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(Supplemental Table 4). Note that the evidence gaps prioritized with the Likert scale process 
overlapped well with the forced-ranking prioritization method.  
Of the 18 top-tier evidence gaps, 8 questions were related to the topic of specific populations or 
subgroup of interest, with the questions of effectiveness of CRT among patients with 
comorbidities (gap #6) and the effectiveness of CRT among patients with atrial fibrillation (AF) 
(gap #5) ranking highest. A total of seven evidence gaps were related to the topic of comparative 
effectiveness and safety of CRT interventions or comparators, and three gaps were related to the 
association of CRT treatment with specific outcomes (Table 1). All of the top-tier questions 
included stakeholders from diverse perspectives. Overall the top-tier evidence gaps ranked by the 
complete stakeholder group remained within the top tier for the various stakeholder groups – 
although the order of these gaps changed (Supplemental Table 5). Exceptions to this 
consistency included evidence gaps that focused on prediction of early death (evidence gap 37), 
reduction in cost (evidence gap 34), and reduction in sudden cardiac death (evidence gap 33) 
which were prioritized by our patient/public stakeholders but were considered second-tier 
priority by the complete group of stakeholders. 
Horizon Scan of Potential Studies Relevant to Top-Tier Evidence Gaps  
Our literature search identified 2,617 potentially relevant articles. Of these, 306 met 
our inclusion criteria, consisting of 44 RCTs of unique original trials or secondary analyses of 
original trials and 262 prospective cohort studies. The sample size of the included studies ranged 
from 10 to more than 10,000 patients. 
On clinicaltrials.gov we found 236 ongoing or completed studies related to CRT research. A 
total of 89 (76 completed, 13 ongoing) studies met our inclusion criteria and were applicable to 
one of the 18 top-tier research priorities. All 18 top-tier research gaps were covered by at least 
one pending or completed clinical study.  
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Supplemental Table 6 describes the included studies, number of patients, and objectives. 
Table 2 summarizes the number of published RCT and observational studies as well as 
ongoing/completed clinical trials for each evidence gap. These results show a paucity of trials 
examining the top 8 priority questions, with one notable exception: the association between 
comorbidities and CRT effectiveness. However, there was significant heterogeneity across the 
trials in relation to sample size and definitions of factors and outcomes. For example, completed 
trials (in clinicaltrials.gov) related to comorbidities and CRT effectiveness had sample sizes 
ranging from 6 to 2,200 patients, and the comorbidities included diabetes, kidney disease, and 
pulmonary hypertension.  
 
DISCUSSION 
      Of the 18 top-tier evidence gaps, the association of comorbidities with CRT effectiveness 
ranked highest. The evidence that led to the approval and initial adoption of CRT in clinical 
practice stemmed from RCTs that either excluded patients with certain comorbid clinical 
conditions or were underpowered to establish the efficacy of CRT in important patient 
subgroups. However, patients with a substantial burden of comorbidities are frequently 
encountered by clinicians who, in the absence of data, often struggle with how to present the 
potential benefits of CRT. Thus, it is not surprising that the question about CRT effectiveness 
among patients with commonly encountered comorbid conditions (gap #6) was the top-tier 
evidence gap. The importance of this gap is further highlighted by the lower implantation rates of 
CRT among patients with common comorbid conditions. While lower rates could be due to the 
perceived higher procedural complications and concerns over competing risks of non-cardiac 
death, the paucity of data and conflicting data on outcomes of CRT in these patients also likely 
play a role (25). A total of 36 findings for gap #6 demonstrated variable results, mostly 
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suggesting that CRT was beneficial for patients with commonly encountered comorbid 
conditions such as diabetes mellitus or chronic kidney disease. Some studies, however, suggested 
a lack of benefit, warranting further investigation. Several comorbid conditions such as end-stage 
renal disease, right ventricular dysfunction, pulmonary hypertension, and other lung diseases had 
little evidence evaluating CRT effectiveness.  
Two of the top-tier gaps relate to patients with AF, gap #5 (effectiveness of CRT among 
patients with paroxysmal, persistent, and permanent AF) and gap #16 (association between AV 
node ablation and CRT effectiveness among patients with AF). About one in four CRT patients 
has AF (26), yet evidence on the effectiveness of CRT for such patients is limited mainly to 
secondary analyses of RCTs and national registries (27,28). Whereas analyses of RCTs suggest 
less benefit from CRT in patients with AF and atrial flutter (26,29), a retrospective analysis of 
the U.S. National Cardiovascular Data Registry indicated lower rates of mortality, all-cause 
readmission, and HF readmission among eligible patients with CRT-D (CRT plus ICD) when 
compared with ICD alone; however, this analysis may have suffered from residual confounding 
and selection bias (30). Our literature search identified 5 RCTs (with 71 to 229 patients included 
in these RCTs), 17 prospective observational studies (with 22 to 9,122 patients), and 3 ongoing 
trials that are potentially applicable to evidence gaps in the treatment of patients with AF. 
Published literature mostly suggests less benefit from CRT in patients with AF, with insufficient 
evidence on AF subtypes and the effect of device-specific pacing modes on outcomes. Current 
clinical guidelines provide a class IIa (level of evidence B) recommendation for atrioventricular 
(AV) node ablation with CRT in patients with AF (31). However, the role of AV node ablation 
for the management of AF in the setting of CRT requires additional exploration, especially in 
relation to selecting appropriate patients and the timing of CRT (32,33). The apparent benefit of 
CRT in these trials may reflect the deleterious effects of RV pacing in the control group in some 
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of these studies (34). The atrio-ventricular component of resynchronisation that optimizes 
ventricular filling and reduces diastolic mitral regurgitation may be a key effect of CRT for many 
patients with HFrEF that bi-ventricular pacing alone cannot deliver. 
Another top-tier evidence gap relates to the relationship between sex, QRS morphology and 
duration, and outcomes for patients with either CRT-P (CRT plus pacemaker) or CRT-D (gap 
#4). While it has been suggested that women derive greater benefit from CRT (35,36), some 
reports suggest they are less likely to receive one (37). Some have suggested that sex disparities 
in CRT-use is because women are less likely to meet the selection criteria such as typical left 
bundle branch block (LBBB), but the reported sex disparities are likely to be  multifactorial (38). 
Our horizon scan found 23 RCT-based analyses or prospective observational studies that 
explored this question, and an ongoing medium-sized clinical trial (clinicaltrials.gov 
NCT02344420). More dedicated research is needed to address this possible health care 
inequality. 
Important clinical topics are covered by gap #22 (is upgrade from a dual chamber pacemaker 
or defibrillator to a CRT device associated with HF-free survival among patients with a high 
burden of right ventricular pacing?) and gap #24 (left ventricular ejection fraction [LVEF] 
threshold at which CRT is superior to dual chamber pacing in high grade or complete AV block). 
It is well established that a large percentage of pacing in the right ventricle can impair cardiac 
function and induce HF in about 30% of patients (39). Current guidelines recommend 
biventricular pacing in patients with an LVEF of ≤50% and concomitant requirement for 
ventricular pacing of >40% (40). While small trials have suggested no benefit of preventive 
biventricular pacing for patients with a normal LVEF (>50%) on mortality and HF 
hospitalizations (41,42), the BLOCK-HF (biventricular versus right ventricular pacing in heart 
failure patients with atrioventricular block) trial showed benefit from biventricular pacing in 
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patients with HF and a left ventricular EF (LVEF) of <50% (43). However, the BIOPACE 
(biventricular pacing for atrioventricular block to prevent cardia desynchronization) trial failed to 
show a significant improvement in outcomes with CRT compared with right ventricular pacing 
in patients with AV block (44). Because the full trial results have not been published, it is 
difficult to interpret these findings. Our horizon scan uncovered 24 published articles on these 2 
related questions, with a limited number of dedicated RCTs. Clinicians and patients often 
struggle to make the important decision of what device type to implant, and professional 
societies and as well as policymakers are unable to make evidence-guided recommendations and 
coverage choices. Therefore, there is a need for more research in this area especially around 
early identification of patients with a deterioration in left ventricular function following chronic 
right ventricular pacing, and the level of ventricular pacing that should trigger the need for CRT. 
Limitations 
Despite our efforts to be comprehensive, other research needs will be identified in the future 
in the light of new technology and understanding.  Further, the number of stakeholders we 
engaged was limited, and a different group of stakeholders could have potentially ranked the 
future research needs differently. However, our stakeholder group was comprised of a diverse 
panel of experts representing a range of perspectives, with a specific focus on patient-centered 
research. It is possible that as part of our systematic review we either missed or misclassified 
studies and the related knowledge gaps; however, our team has extensive experience with 






The prioritized evidence gaps presented in this paper highlight numerous, highly relevant 
unanswered clinical and policy questions on the role of CRT. Following this prioritization 
process, the ESG team will continue to collaborate with principal investigators from existing 
trials of CRT to harness the power of patient-level data from more than 10 years of clinical trials 
representing nearly 10,000 patients. As part of an ongoing collaboration funded by NHLBI 
(1R01HL131754), we are creating combined data set of the individual patient data from each of 
the trials, and using Bayesian statistics and decision modeling we are exploring the top three 
prioritized key uncertainties identified in this manuscript. This collaboration among our team, the 
PIs of the key trials, and the different companies – and inclusion of patient level data -- is 
unprecedented. Initial analyses will focus on the highest prioritized topics including: the 
association between comorbid diseases and the effectiveness of CRT therapies, the effectiveness 
of CRT among patients with atrial fibrillation, and the relationship between sex, QRS duration 





Competency in Medical Knowledge: Of the 18 top-tier evidence gaps we identified, 8 were 
related to specific populations or subgroups of interest. Seven gaps were related to the 
comparative effectiveness and safety of CRT interventions or comparators, and three gaps were 
related to the association of CRT treatment with specific outcomes. The association of 
comorbidities with CRT effectiveness ranked highest, followed by questions about the 
effectiveness of CRT among patients with atrial fibrillation and the relationship between gender, 
QRS morphology and duration, and outcomes for patients with either CRT-D or ICD. 
Translational Outlook: The prioritized evidence gaps presented in this paper highlight 
numerous highly relevant unanswered clinical and policy questions on the role of CRT, which 
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Table 1. Ranked CRT Evidence Gaps 
 
Top-tier evidence gaps are shaded gray. These gaps correspond to those in the top third (i.e., top 
14 evidence gaps) as indicated by forced ranking or that were rated as being critical to decision 
making by more than 40% of stakeholders (adding in an additional 4 gaps).  
 
Evidence Gap Score Stakeholders N Perspectives 
6. What is the association between 
comorbid diseases (e.g., chronic kidney 
disease, chronic lung disease, atrial 
fibrillation, diabetes mellitus, arterial and 
pulmonary hypertension, right 
ventricular dysfunction, and patients on 
dialysis) as well as the burden of 
comorbidities and the effectiveness of 
CRT-P and CRT-D? 
19 13 9 healthcare providers, 9 
researchers/investigators, 1 
device manufacturer, 2 
patients/public, 1 Other, 1 
policymaker 
5. What is the effectiveness of CRT 
among patients with paroxysmal, 
persistent, and permanent AF? 
18 12 7 healthcare providers, 8 
researchers/investigators, 1 
device manufacturer, 1 
patient/public, 1 Other, 1 
policymaker 
4. What is the relationship between 
gender, QRS morphology and duration, 
and outcomes for patients with either 
CRT-D or ICD? 
17 11 7 healthcare providers, 9 
researchers/investigators, 1 
device manufacturer, 1 
patient/public, 1 Other, 1 
policymaker 
24. What is the EF threshold at which 
CRT is superior to dual chamber pacing 
in high grade or complete AV block? 
17 11 7 healthcare providers, 9 
researchers/investigators, 1 
patient/public, 1 Other, 1 
device manufacturer, 1 
policymaker 
11. What is the comparative safety and 
effectiveness of CRT compared with no 
CRT among patients with a LBBB and 
EF >35%? 
16 7 6 healthcare providers, 4 
researchers/investigators, 1 
patient/public, 1 policymaker 
16. What is the association between AV 
node ablation (vs. no AV node ablation) 
and CRT effectiveness among patients 
with AF and history of AF with rapid 
ventricular response? 
15 9 6 healthcare providers, 6 
researchers/investigators, 1 
patient/public, 2 device 
manufacturers 
1. What is the comparative safety and 
effectiveness of CRT (vs. no CRT) 
among patients ≥75 years old? ≥80 
years old? 
14 9 8 healthcare providers, 6 
researchers/investigators, 1 
patient/public, 1 Other 
17. What is the minimum percentage of 
biventricular pacing required for CRT-D 
to be superior to ICD? 
13 10 6 healthcare providers, 8 
researchers/investigators, 1 
patient/public, 1 policymaker 
32. What is the predictive accuracy of a 
model that includes available clinical, 
ECG, echocardiography, and device 
parameters associated with 
improvement in overall survival in 
patients with CRT? 





Evidence Gap Score Stakeholders N Perspectives 
22. Is upgrade from a dual chamber 
pacemaker or defibrillator to a CRT 
device (vs. no upgrade) associated with 
HF free survival among patients with a 
high burden of RV pacing? 
12 8 4 healthcare providers, 7 
researchers/investigators, 1 
patient/public, 1 Other, 1 
device manufacturer 
8. Does CRT benefit (compared to no 
CRT) vary based on QRS duration 
(<150ms vs ≥ 150ms)? 
11 6 2 healthcare providers, 5 
researchers/investigators, 1 
patient/public, 2 device 
manufacturers, 1 policymaker 
26. Does CRT (compared to ICD) 
improve survival in very advanced HF as 
demonstrated by NYHA class and/or LV 
size/function? 
11 6 4 healthcare providers, 4 
researchers/investigators, 1 
patient/public, 1 Other 
13. What is the comparative safety and 
effectiveness of CRT-D versus CRT-P 
overall and among subgroups defined 
by cardiomyopathy etiology and QRS 
morphology? 
10 5 4 healthcare providers, 3 
researchers/investigators, 1 
patient/public, 1 device 
manufacturer 
18. What is the optimal percentage of 
biventricular pacing required to optimize 
outcomes among CRT recipients? 
10 7 4 healthcare providers, 6 
researchers/investigators, 1 
patient/public 
29. What is the predictive accuracy of a 
model that includes available clinical, 
ECG, echocardiography, and device 
parameters associated with 
improvement in quality of life and 
functional status in patients with CRT? 
10 5 3 healthcare providers, 3 
researchers/investigators, 1 
patient/public 
19. What is the association of PVC 
burden prior and post CRT-D 
implantation on outcomes? Any data on 
associations of PVC ablation and 
outcomes? 
8 7 3 healthcare providers, 6 
researchers/investigators, 2 
patients/public, 1 Other, 1 
policymaker 
3. Do CRT outcomes differ based on 
patient race and ethnicity? 
7 6 4 healthcare providers, 5 
researchers/investigators, 1 
device manufacturer 
20. Is the PR interval associated with 
the effectiveness of CRT (vs. no CRT)? 
7 5 4 healthcare providers, 4 
researchers/investigators 
31. What is the predictive accuracy of a 
model that includes available clinical, 
ECG, echocardiography, and device 
parameters associated with reductions 
in heart failure (HF) hospitalizations in 
patients with CRT? 
7 4 2 healthcare providers, 3 
researchers/investigators 
28. What is the role of endocardial CRT 
especially in “non-responders” and with 
the advent of novel oral anticoagulants 
(NOACs)? 
6 4 2 healthcare providers, 4 
researchers/investigators, 1 
patient/public, 1 Other 
14. In looking at the control arms of the 
available CRT trials, which patients are 
at the highest risk of heart failure or 
death? 
5 3 3 healthcare providers, 2 
researchers/investigators, 1 
device manufacturer 
21. Is AV delay programming and/or 
CRT optimization associated with any 




Evidence Gap Score Stakeholders N Perspectives 
observed relationship between PR 
interval and outcomes among CRT 
patients? 
25. Does RV lead location predict 
outcomes among CRT patients? 
5 3 3 healthcare providers, 3 
researchers/investigators 
33. What is the predictive accuracy of a 
model that includes available clinical, 
ECG, echocardiography, and device 
parameters associated with reduction in 
the risk of sudden cardiac death in 
patients with CRT? 
5 4 2 healthcare providers, 2 
researchers/investigators, 1 
patient/public 
34. What is the predictive accuracy of a 
model that includes available clinical, 
ECG, echocardiography, and device 
parameters associated with reduction of 
cost in patients with CRT? 
5 3 1 healthcare provider, 3 
researchers/investigators, 1 
patient/public 
37. What are the echocardiographic 
predictors of early death (within 30 days) 
after CRT implantation (i.e. are there 
echocardiographic predictors of CRT 
futility)? 
5 3 1 healthcare provider, 3 
researcher/investigator, 2 
patients/public, 1 Other, 1 
policymaker 
39. Do outcomes and complications vary 
based on timing relative to prior heart 
failure hospital admission? 
5 4 1 healthcare provider, 3 
researchers/investigators, 2 
patients/public, 1 Other, 1 
device manufacturer 
40. Are the CRT outcomes observed in 
the community predicted by the 
available clinical trial evidence? 
5 5 3 healthcare providers, 4 
researchers/investigators, 1 
patient/public, 1 Other, 1 
policymaker 
2. What is the association between heart 
failure duration and history of heart 
failure hospitalizations prior to 
implantation of CRT (vs. no CRT) with 
outcomes? 
4 3 3 healthcare providers, 2 
researchers/investigators 
9. Do the location and extent of left 
ventricular dyssynchrony predict 
outcomes among CRT patients? 
4 3 2 healthcare providers, 2 
researchers/investigators, 1 
device manufacturer 
10. What is the relationship between 
height, weight, BMI, diabetes, and 
outcomes of CRT-D vs. ICD (i.e. does 
the obesity paradox apply to CRT 
patients and does diabetes modify this 
relationship)? 
4 4 3 healthcare providers, 2 
researchers/investigators 
12. Is CRT more effective than an ICD 
at halting progressive remodeling in the 
subset of HF patients who do not 
demonstrate classic echocardiographic 
response (defined as 15% improvement 
in LV end systolic volume)? 
4 4 2 healthcare providers, 4 
researchers/investigators 
15. In looking at the control arms of the 
available CRT, what are the predictors 
of worsening LVEF? 





Evidence Gap Score Stakeholders N Perspectives 
7. What is the relationship between 
chronic lung disease, receipt of CRT vs. 
no CRT, and outcomes, particularly 
symptom burden and quality of life? 
3 3 3 healthcare providers, 1 
researcher/investigator 
23. Is there an association between time 
since MI/revascularization and CRT 
outcomes? 
3 2 1 healthcare provider, 2 
researchers/investigators, 1 
patient/public, 1 Other 
27. Is LV end systolic volume superior to 
EF at predicting whether CRT is 
superior to dual chamber pacing in high 
grade or complete AV block? 
3 3 3 healthcare providers, 2 
researchers/investigators 
30. What is the predictive accuracy of a 
model that includes available clinical, 
ECG, echocardiography, and device 
parameters associated with a short term 
and durable improvement in LVEF and 
other echocardiographic parameters in 
patients with CRT? 
3 3 2 healthcare providers, 2 
researchers/investigators 
36. What are the rates and predictors of 
appropriate and inappropriate ICD 
therapy events (shocks and/or ATP) 
among patients with CRT-D vs. ICD 
only? 
1 1 1 researcher/investigator, 1 
patient/public, 1 Other 
38. What is the distribution of modes of 
death in responders vs. non-responders 
to CRT? 
1 1 1 researcher/investigator, 1 
patient/public, 1 Other 
35. What is the predictive accuracy of a 
model that includes available clinical, 
ECG, echocardiography, and device 
parameters associated with reduction in 
atrial and ventricular arrhythmias in 
patients with CRT? 
0 0 NA 
Abbreviations: AF=atrial fibrillation; ATP=antitachycardia pacing; AV=atrioventricular; 
CRT=cardiac resynchronization therapy; CRT-D=CRT with ICD; CRT-P=CRT with pacemaker; 
ECG=electrocardiogram; EF=ejection fraction; HF=heart failure; ICD=implantable cardiac 
device; LBBB=left bundle branch block; LVEF=left ventricular ejection fraction; NYHA=New 
York Heart Association; PVC=premature ventricular contraction; RCT=randomized controlled 
trial; RV=right ventricular  
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Table 2. Number of Potentially Relevant Studies for Top Tier Evidence Gaps 
 
Evidence Gap Topic 
(in Ranked Order) 











6. What is the association between comorbid 
diseases (e.g., chronic kidney disease, 
chronic lung disease, atrial fibrillation, 
diabetes mellitus, arterial and pulmonary 
hypertension, right ventricular dysfunction, 
and patients on dialysis) as well as the 
burden of comorbidities and the 
effectiveness of CRT-P and CRT-D? 
3 33 10 2 
5. What is the effectiveness of CRT among 
patients with paroxysmal, persistent, and 
permanent AF? 
4 12 3 1 
4. What is the relationship between gender, 
QRS morphology and duration, and 
outcomes for patients with either CRT-D or 
ICD? 
5 18 6 2 
24. What is the EF threshold at which CRT is 
superior to dual chamber pacing in high 
grade or complete AV block? 
3 3 2 0 
11. What is the comparative safety and 
effectiveness of CRT compared with no CRT 
among patients with a LBBB and EF >35%? 
0 6 1 2 
16. What is the association between AV node 
ablation (vs. no AV node ablation) and CRT 
effectiveness among patients with AF and 
history of AF with rapid ventricular 
response? 
3 8 3 2 
1. What is the comparative safety and 
effectiveness of CRT (vs. no CRT) among 
patients ≥75 years old? ≥80 years old? 
1 17 8 1 
17. What is the minimum percentage of 
biventricular pacing required for CRT-D to 
be superior to ICD? 
2 1 3 0 
32. What is the predictive accuracy of a model 
that includes available clinical, ECG, 
echocardiography, and device parameters 
associated with improvement in overall 
survival in patients with CRT? 
13 103 24 2 
22. Is upgrade from a dual chamber 
pacemaker or defibrillator to a CRT device 
(vs. no upgrade) associated with HF free 
survival among patients with a high burden 
of RV pacing? 
4 9 5 0 
8. Does CRT benefit (compared to no CRT) 
vary based on QRS duration (<150ms vs ≥ 
150ms)? 
1 13 9 0 
26. Does CRT (compared to ICD) improve 
survival in very advanced HF as 
demonstrated by NYHA class and/or LV 
size/function? 
2 16 4 0 
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Evidence Gap Topic 
(in Ranked Order) 











13. What is the comparative safety and 
effectiveness of CRT-D versus CRT-P 
overall and among subgroups defined by 
cardiomyopathy etiology and QRS 
morphology? 
2 20 3 0 
18. What is the optimal percentage of 
biventricular pacing required to optimize 
outcomes among CRT recipients? 
2 4 3 0 
29. What is the predictive accuracy of a model 
that includes available clinical, ECG, 
echocardiography, and device parameters 
associated with improvement in quality of life 
and functional status in patients with CRT? 
12 55 48 3 
19. What is the association of PVC burden 
prior and post CRT-D implantation on 
outcomes? Any data on associations of PVC 
ablation and outcomes? 
2 1 1 0 
20. Is the PR interval associated with the 
effectiveness of CRT (vs. no CRT)? 1 7 5 0 
40. Are the CRT outcomes observed in the 
community predicted by the available clinical 
trial evidence? 
2 14 3 0 
* Unique original RCTs or secondary analyses of original RCTs 
Abbreviations: AF=atrial fibrillation; AV=atrioventricular; CRT=cardiac resynchronization 
therapy; ECG=electrocardiogram; EF=ejection fraction; HF=heart failure; ICD=implantable 
cardiac device; LBBB=left bundle branch block; LVEF=left ventricular ejection fraction; 
NYHA=New York Heart Association; PVC=premature ventricular contraction; 




(Central Illustration) Figure 1. Overview of Prioritization Process 
 
Abbreviations: CRT=cardiac resynchronization therapy; ESG=Evidence Synthesis Group 
